Showing results (981-990 of 1,030) with videos related to
Sort By:
Pageof 103
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.Journal of Neuro-Oncology|January 7, 2023
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trialJ Weller, N Schäfer, C Schaub, et al.BMJ Open|August 14, 2024
DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patientsJoosje C Baltussen, Frederiek van den Bos, Marije Slingerland, et al.Annals of Intensive Care|May 16, 2019
Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort studyLaura R Schouten, Anton H van Kaam, Franziska Kohse, et al.Neurological Research and Practice|July 24, 2025
Decoding glioblastoma survival: unraveling the prognostic potential of olfactory function in a prospective observational studyChristoph Oster, Aylin Matyar, Teresa Schmidt, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 2022
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Rainer Hamacher, Miriam Sraieb, et al.Journal of Neuro-Oncology|July 21, 2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trialSied Kebir, Christina Schaub, Nina Junold, et al.Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.EMBO Molecular Medicine|December 16, 2015
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastomaAlexander Scholz, Patrick N Harter, Sebastian Cremer, et al.Breast Cancer Research and Treatment|September 27, 2008
Validation of 70-gene prognosis signature in node-negative breast cancerJ M Bueno-de-Mesquita, S C Linn, R Keijzer, et al.Pageof 103